Objective: Endogenous peptide YY ) is associated with postprandial regulation of appetite. We investigated the safety and effectiveness of peripherally administered synthetic human PYY 3-36 for 14 days in New Zealand white rabbits. Weight gain and food consumption were assessed and pharmacokinetics and toxicity characterized. Research methods and procedures: In all, 24 animals were randomized to one of four intravenous treatment groups -control (0.9% saline) or PYY 3-36 bolus at 4.1, 41.0, or 205 mg/kg/day. Body weight and consumption of fixed food allotment were measured daily. Hematology and serum chemistries were profiled at baseline and Day 15, and pharmacokinetics measured following dose 14. Histopathologic examination of designated tissues and organs in control and PYY 3-36 205 mg/kg animals was conducted. All animals were subject to clinical and macroscopic observation. Results: The trend effect of higher dose PYY 3-36 on lower average weight was significant (P ¼ 0.01; Day 14 compared to baseline) and its effect on reduced food consumption was suggested (P ¼ 0.065; number of days p75% food eaten, compared with control). Hematology and clinical chemistries were within normal limits pretest and at Day 15. No clinical, macroscopic, histologic, or microscopic changes related to the test article were observed over the course of study. Discussion: Lower average weight occurs in rabbits treated once daily with intravenous injection PYY 3-36 (205 mg/kg/day) over 14 days. No clinical or histologic signs of toxicity were observed. Further research is warranted to describe alternate routes of peripheral administration for optimizing weight control.
Introduction
Peptide YY ) is an endogenous hormone, produced by L cells of the gastrointestinal tract and released postprandially in proportion to caloric intake. [1] [2] [3] [4] [5] [6] [7] As a selective Y2 receptor agonist, PYY influences the hypothalamus, including the melanocortin and neuropeptide Y (NPY) systems of the arcuate nucleus, in its regulation of appetite. [7] [8] [9] [10] [11] Intraperitoneal administration of PYY (single dose 0.3 mg/100 g body weight) has been shown in 24-h fasted rats to produce plasma concentrations of PYY within the range of normal postprandial concentrations. 11 Further, significant reduction in cumulative food intake and consequent decreased body weight gain have been reported for rats treated chronically with intraperitoneal PYY (5.0 mg/100 g body weight, twice daily for 7 days) when compared to a control population. 11 In humans, a significant inhibition of food intake for a period of 12 h and a decrease in cumulative 24-h caloric intake by obese and lean subjects has been reported following a single peripheral infusion of PYY (total dose, 2 nmol/m 2 body-surface area). 12 The present study was performed to characterize the pharmacokinetics, and investigate toxicity, food consumption, and reduction in weight gain effects, of chronic peripheral administration of synthetic human PYY 3-36 at three dose levels over 14 consecutive days in rabbits.
Methods
In all, 24 New Zealand White rabbits (12 each male and female; Myrtles Rabbitry Inc.), ages 12-14 weeks and weighing 2.5-2.8 kg, were used in this study. The animals were housed individually in stainless-steel cages and environmental conditions were maintained according to published practices of good animal husbandry. 13 The study was Hematology and fasting serum chemistry profiles (Table 1) were collected for all animals on Day 1 prior to the first intravenous dose, and on Day 15. Venous blood samples for pharmacokinetics were drawn on Day 14 from all animals before, and 2, 5, 10, 15, 30, and 45 min after, intravenous injection of the study agent. Venous access was via jugular vein or the marginal vein of the ear contralateral to that used for injection. Blood samples (2 ml) were transferred to laboratory test tubes containing potassium EDTA (Becton, Dickenson and Company, Franklin Lakes, NJ, USA) and protease inhibitor, aprotinin (0.6 TIU/ml; 50 ml/ml whole blood; MP Biomedicals, Irvine, CA, USA). Plasma was separated and dispensed into aliquots following centrifugation at 2366 r.p.m. at 41C for approximately 15 min. Aliquots were frozen at À701C.
All animals were anesthetized on Day 15 by intramuscular injection of ketamine hydrochloride (20 mg/kg) and xylazine (10 mg/kg; Vedco, St Joseph, MO, USA), euthanized by exsanguination, and examined. Macroscopic lesions identified on examination and designated tissues and organs (Table 2) were excised and preserved in 10% neutral-buffered formalin. Representative sections of designated tissues and organs collected from all Group I and Group IV animals were routinely processed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin for microscopic evaluation. Histopathology processing, preparation, and evaluation were performed in accordance with the laboratory's standard operating procedures (Research Pathology Services Inc.) and audited in compliance with GLP.
Test and control articles
Test drug article was synthetic human PYY (Bachem California, Torrance, CA, USA), formulated to concentrations of 10.25, 102.5, and 512.5 mg/ml. Sterile normal saline solution (0.9%) was used as the control article. PYY formulations were stored at 2-81C. Single lot numbers of test and control articles were used for each study group throughout the 14-dose regimen.
Radioimmunoassay of PYY 3-36
Concentration of plasma synthetic human PYY 3-36 was determined using radioimmunoassay methods developed and validated by our laboratory. Calibrators and controls were constituted in matrices identical to experimental samples, and stripped of endogenous PYY. Plasma samples and constituted calibrators and controls were extracted in alcohol, evaporated under vacuum, and resuspended in a standard phosphate buffer with aprotinin. Each was then (Figure 1 ).
Weight gain and food consumption
A significant trend of lower average weight for animals was associated with higher dose PYY 3-36 at Day 14, compared to Day 1, adjusted for baseline weight, sex, and assigned squad (P ¼ 0.01) (Figure 2 ). When animal 919 (Group IV) was removed due to a large value for Cook's D (influential observation), the trend effect of the higher dose PYY 3-36 on lower average weight was highly significant (P ¼ 0.0001). A trend for reduced food consumption was suggested for higher doses PYY 3-36 when dose groups were compared with the number of days that animals ate p75% food (P ¼ 0.065) or with the proportion of animals that ate p75% food for a minimum of 1 day (P ¼ 0.14).
Normative data for food consumption is 50 g/kg/day and 110 cal/kg/day for basal metabolism for New Zealand White rabbits. All the animals weighed approximately 2.7-2.8 kg (0.1) on Day 1. Using the Kleiber equation for maintenance requirements (70 Wkg 0.75 ), for a 2.7-2.8 kg rabbit, the average energy maintenance requirements would be 150 kcal/day for all animals per group. The ratio of food consumed to basal metabolism and maintenance is independent of body weight and therefore the calories of tissue formed per 100 calories of food consumed are about the same for all the rabbits in the study. The rate of gain is proportional to metabolic size and is approximately the same for all rabbits in the study at a weight of 2.7-2.8 kg on Day 1 using the equation Wkg 0.75 .
The rabbits were fed 150 g of a diet containing 3.67 kcal/g of gross energy and 1.99 kcal/g of metabolizable energy. Therefore, a rabbit that ate 150 g of diet would have an available 298.5 kcal of metabolizable energy per day or energy intake efficiency for maintenance and weight gain. Since the animals weighed approximately the same (2.7270.1) when entering the study, their food consumption, basal metabolism, and energy maintenance needs should be the same for all groups and should not affect group comparisons on body weight gain and food consumption. Lower average weight after 14 days PYY 3-36 AP Sileno et al Energy expenditure and body composition at necropsy was not evaluated.
Since food consumption was based on an estimation key and not weight, we found eight instances in Group IV where 25% of the food was remaining and only one instance in the control. Therefore, the changes in body weight across groups are most likely due to food consumption between groups.
Safety and tolerance
Two animals (one female, one male) in Group III developed tachypnea and bilateral reddening of ears following intravenous dose of PYY 3-36 at 41.0 mg/kg, subsiding within 30 min and with no observed sequelae. All other animals were observed to be free of abnormal or treatment-related signs of toxicity up to 5 h postinjection. All animals survived to study completion and necropsy.
Hematologic parameters were within normal limits on Day 1 and Day 15 for all animals in all treatment groups. Serum chemistry results for all animals were within normal limits at pretest and following the 14th consecutive days treatment.
Minimal to mild microscopic changes were observed in the intravenous injection sites and surrounding perivascular tissues. Observed changes occurred at similar incidence and severity in both control Group I and test article Group IV (PYY 3-36 at 205 mg/kg). The most common changes in both groups were perivascular mixed inflammatory cell (mononuclear and heterophilic) infiltrations and perivascular Lower average weight after 14 days PYY 3-36 AP Sileno et al hemorrhage, edema, and fibroplasias. In control Group I animals, venous thrombus and focal necrosis were observed in one animal and focal perivascular necrosis in a second. Histomorphologic observations are summarized in Table 3 . Microscopic changes, where observed in designated organs and tissues, were graded as mild to moderate severity, and were considered not related to administration of the test article. No treatment-related differences for individual organ weights (gross, or as a percentage of body weight and brain weight) were identified.
Pulmonary tissues in 11 of 12 animals (Groups I and IV combined) exhibited minimal to mild microscopic changes including multiple foci of interstitial inflammation, hyperplasia of peribronchial and perivascular lymphoid tissues, focal emphysema, foci of pigmented macrophages, and occasional microgranuloma. Interstitial inflammation and microgranulomas of pulmonary tissues are reported to be incidental findings in laboratory animals enrolled in intravenous injection studies. 16 
Discussion
This study demonstrates that lower average weight occurs in rabbits treated once daily with intravenous injection PYY (205 mg/kg daily dose) administered each of 14 consecutive days when compared with saline controls. A suggested trend in reduced food consumption was observed in rabbits provided with a fixed daily food allotment. The diet was appropriate for normal rabbit maintenance and weight gain. Since all the animals entered the study at approximately the same body weight, food consumption, basal metabolism, energy expenditure, and maintenance should be the same for all groups and should not affect group comparisons. Energy expenditure is represented by basal metabolic rate. There is a possibility that PYY 3-36 may also raise basal metabolic rates, thus resulting in weight loss. Lower average weight gain and reduced food consumption have been previously reported for freely feeding rodents treated twice daily with intraperitoneal injection PYY (100 mg/kg daily dose) over 7 days.
11 Dose-dependent and significant inhibition of food consumption has also been demonstrated in mice acclimated to laboratory handling for 1 week prior to receiving a single intraperitoneal dose PYY 3-36 (3.0, 30, and 100 mg/kg).
17
No abnormal clinical or macroscopic laboratory findings were attributed in this study to PYY at any of three tested dose levels (4.1, 41, or 205 mg/kg daily dose). Observations made at histopathology were considered to be incidental or spontaneous in origin and independent of control or active agent. Microscopic changes observed in intravenous injection site and in pulmonary tissues were similar in incidence and severity for both Group I (control) and Group IV animals. All hematology and clinical chemistry values were within normal limits at Day 15 and did not change significantly from those of Day 1 baseline.
Chronic peripheral administration of an active agent to control food consumption and weight may require ondemand dosing for an as-yet-to-be determined regimen. This study suggests peripheral administration of synthetic human PYY 3-36 is associated with no clinical or histologic signs of toxicity after 14 days treatment. Further research is warranted to describe alternate routes of peripheral administration, including intranasal route, with predicted peak concentration and T 1/2 values within the normal physiological range.
